Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11
10 Julio 2023 - 7:30AM
Artelo Biosciences,
Inc.
(Nasdaq: ARTL), a
clinical-stage pharmaceutical company focused on modulating
lipid-signaling pathways to develop treatments for people living
with cancer, pain, and neurological conditions, today announced
that Gregory D. Gorgas, President & Chief Executive Officer of
Artelo Biosciences, will be participating in the Benzinga All
Access event taking place on Tuesday, July 11, 2023.
Mr. Gorgas is scheduled to appear on Tuesday,
July 11, 2023, at 11:00 AM Eastern Time.
The event will be broadcast live and can be
viewed at: https://youtube.com/live/6iF2xONfotE?feature=share. An
archived recording of the presentation will be available on the
investor relations section of the Company’s website at
https://ir.artelobio.com/news-events/ir-calendar.
About Benzinga All Access
Benzinga All Access is a first-of-its-kind show:
part interview, part investor presentation. On All Access, Benzinga
partners with companies to bring you in-depth one-on-one
conversations with executives across a wide range of industries and
asset classes. From emerging biotechs, to alternative real estate
investment platforms, to everything in between, guests on All
Access have one thing in common: they want to tell their story to
investors.
About Artelo BiosciencesArtelo
Biosciences, Inc. is a clinical stage pharmaceutical company
dedicated to the development and commercialization of proprietary
therapeutics that modulate lipid-signaling pathways including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, anxiety, pain, neuropathy, and inflammation. Led by proven
biopharmaceutical executives collaborating with highly respected
researchers and technology experts, the Company applies leading
edge scientific, regulatory, and commercial discipline to develop
high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward-Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and Private
Securities Litigation Reform Act, as amended, including those
relating to the Company’s product development, clinical and
regulatory timelines, market opportunity, competitive position,
possible or assumed future results of operations, business
strategies, potential growth opportunities and other statement that
are predictive in nature. These forward-looking statements are
based on current expectations, estimates, forecasts and projections
about the industry and markets in which we operate and management’s
current beliefs and assumptions. These statements may be identified
by the use of forward-looking expressions, including, but not
limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,”
“estimate,” “potential,” “predict,” “project,” “should,” “would”
and similar expressions and the negatives of those terms. These
statements relate to future events and involve known and unknown
risks, uncertainties, and other factors which may cause actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Such factors include
those set forth in the Company’s filings with the Securities and
Exchange Commission, including our ability to raise additional
capital in the future. Prospective investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this press release. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise, except to the extent required by applicable securities
laws.
Investor Relations
Contact:Crescendo Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Artelo Biosciences (NASDAQ:ARTL)
Gráfica de Acción Histórica
De May 2023 a May 2024